S Schippling1, L J Balk2, F Costello3, P Albrecht4, L Balcer5, P A Calabresi6, J L Frederiksen7, E Frohman8, A J Green9, A Klistorner10, O Outteryck11, F Paul12, G T Plant13, G Traber14, P Vermersch11, P Villoslada15, S Wolf16, A Petzold17. 1. Neuroimmunology and MS Research Section, University Hospital Zurich, Switzerland. 2. MS Centre Amsterdam, VU University Medical Centre, The Netherlands. 3. University of Calgary, Canada. 4. Medical Faculty, Heinrich-Heine University Düsseldorf, Germany. 5. New York University School of Medicine, New York, USA. 6. Johns Hopkins Hospital, Baltimore, MD, USA. 7. University of Copenhagen, Denmark. 8. University of Texas Southwestern Medical Center at Dallas, USA. 9. MS Center, University of California San Francisco, USA. 10. Save Sight Institute, University of Sydney, Australia. 11. University of Lille Nord de France, France. 12. NeuroCure Clinical Research Center (NCRC) and Clinical and Experimental MS Research Center, Charite, Universitätsmedizin Berlin, Germany. 13. Moorfields Eye Hospital, The National Hospital for Neurology and Neurosurgery and St. Thomas' Hospital, London, UK. 14. University Hospital Zurich, Switzerland. 15. Center for Neuroimmunology, Institute of Biomedical Research August, Pi Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain. 16. Bern University Hospital and University of Bern, Switzerland. 17. MS Centre Amsterdam, VU University Medical Centre, The Netherlands a.petzold@vumc.nl.
Abstract
BACKGROUND: Retinal optical coherence tomography (OCT) permits quantification of retinal layer atrophy relevant to assessment of neurodegeneration in multiple sclerosis (MS). Measurement artefacts may limit the use of OCT to MS research. OBJECTIVE: An expert task force convened with the aim to provide guidance on the use of validated quality control (QC) criteria for the use of OCT in MS research and clinical trials. METHODS: A prospective multi-centre (n = 13) study. Peripapillary ring scan QC rating of an OCT training set (n = 50) was followed by a test set (n = 50). Inter-rater agreement was calculated using kappa statistics. Results were discussed at a round table after the assessment had taken place. RESULTS: The inter-rater QC agreement was substantial (kappa = 0.7). Disagreement was found highest for judging signal strength (kappa = 0.40). Future steps to resolve these issues were discussed. CONCLUSION: Substantial agreement for QC assessment was achieved with aid of the OSCAR-IB criteria. The task force has developed a website for free online training and QC certification. The criteria may prove useful for future research and trials in MS using OCT as a secondary outcome measure in a multi-centre setting.
BACKGROUND: Retinal optical coherence tomography (OCT) permits quantification of retinal layer atrophy relevant to assessment of neurodegeneration in multiple sclerosis (MS). Measurement artefacts may limit the use of OCT to MS research. OBJECTIVE: An expert task force convened with the aim to provide guidance on the use of validated quality control (QC) criteria for the use of OCT in MS research and clinical trials. METHODS: A prospective multi-centre (n = 13) study. Peripapillary ring scan QC rating of an OCT training set (n = 50) was followed by a test set (n = 50). Inter-rater agreement was calculated using kappa statistics. Results were discussed at a round table after the assessment had taken place. RESULTS: The inter-rater QC agreement was substantial (kappa = 0.7). Disagreement was found highest for judging signal strength (kappa = 0.40). Future steps to resolve these issues were discussed. CONCLUSION: Substantial agreement for QC assessment was achieved with aid of the OSCAR-IB criteria. The task force has developed a website for free online training and QC certification. The criteria may prove useful for future research and trials in MS using OCT as a secondary outcome measure in a multi-centre setting.
Authors: Angeliki Filippatou; Thomas Shoemaker; Megan Esch; Madiha Qutab; Natalia Gonzalez-Caldito; Jerry L Prince; Ellen M Mowry; Peter A Calabresi; Shiv Saidha; Elias S Sotirchos Journal: Mult Scler Date: 2018-12-03 Impact factor: 6.312
Authors: Athina Papadopoulou; Laura Gaetano; Armanda Pfister; Anna Altermatt; Charidimos Tsagkas; Felix Morency; Alexander U Brandt; Martin Hardmeier; Mallar M Chakravarty; Maxime Descoteaux; Ludwig Kappos; Till Sprenger; Stefano Magon Journal: Neurology Date: 2019-04-10 Impact factor: 9.910
Authors: Basanta Bhaduri; Ryan M Nolan; Ryan L Shelton; Lara A Pilutti; Robert W Motl; Stephen A Boppart Journal: J Biomed Opt Date: 2016-09-01 Impact factor: 3.170
Authors: Angeliki G Filippatou; Jeffrey Lambe; Elias S Sotirchos; Kathryn C Fitzgerald; Andrew Aston; Olwen C Murphy; Nicole Pellegrini; Nicholas Fioravante; Hunter Risher; Esther Ogbuokiri; Ohemaa Kwakyi; Brandon Toliver; Simidele Davis; Nicholas Luciano; Ciprian Crainiceanu; Jerry L Prince; Ellen M Mowry; Peter A Calabresi; Shiv Saidha Journal: Mult Scler Date: 2020-04-16 Impact factor: 6.312
Authors: Vivek Vijay; Susan P Mollan; James L Mitchell; Edward Bilton; Zerin Alimajstorovic; Keira A Markey; Anthony Fong; Jessica K Walker; Hannah S Lyons; Andreas Yiangou; Georgios Tsermoulas; Kristian Brock; Alexandra J Sinclair Journal: JAMA Ophthalmol Date: 2020-12-01 Impact factor: 7.389